Abstract
Summary The revolutionary gene editing technology CRISPR-Cas is on the verge of widespread application in agriculture, promising easy access to dramatic crop improvements. Companies now licensing the technology face the challenge of regaining the public trust that was lost in the GM debate. Additional insecurity comes from the ongoing patent dispute between two renowned US institutions. Michael Gross reports.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
